Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The immunophenotypic characteristics of plasma cells include surface expression of CD138, elevated levels of CD38, a general marker of lymphocytic activation, and down-regulation of CD20 [28].”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 25
- Tatsas, 2010, Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis?, Am J Clin Pathol, 134, 139, 10.1309/AJCP69TCAVDGSCWI · DOI
- Guikema, 2004, Heterogeneity in the multiple myeloma tumor clone, Leuk Lymphoma, 45, 857, 10.1080/10428190310001593201 · DOI
- Bataille, 2006, The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas†and of new targets for myeloma therapy, Haematologica, 91, 1234
- Raja, 2010, Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders, Br J Haematol, 149, 334, 10.1111/j.1365-2141.2010.08121.x · DOI
- Cannizzo, 2010, Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology, Cytometry B Clin Cytom, 78, 231, 10.1002/cyto.b.20517 · DOI
- Rawstron, 2006, Immunophenotyping of plasma cells, Curr Protoc Cytom, 6, 6.23, 10.1002/0471142956.cy0623s36 · doi:10.1002/0471142956.cy0623s36
- Robillard, 2013, A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma, Blood Cancer J, 3, e134, 10.1038/bcj.2013.33 · doi:10.1038/bcj.2013.33
- Peceliunas, 2011, Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors, Cytometry B Clin Cytom, 80, 318, 10.1002/cyto.b.20601 · DOI
- Medina, 2002, The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression, Blood, 99, 2154, 10.1182/blood.V99.6.2154 · DOI · Paper page
- Mateo, 2005, Genetic abnormalities and patterns of antigenic expression in multiple myeloma, Clin Cancer Res, 11, 3661, 10.1158/1078-0432.CCR-04-1489 · doi:10.1158/1078-0432.ccr-04-1489
- Magrangeas, 2013, Minor clone provides a reservoir for relapse in multiple myeloma, Leukemia, 27, 473, 10.1038/leu.2012.226 · DOI · Paper page
- Arnoulet, 2010, Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL, Cytometry B Clin Cytom, 78, 4, 10.1002/cyto.b.20484 · doi:10.1002/cyto.b.20484
- Moreau, 2004, Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma, Haematologica, 89, 547
- Liu, 2012, Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma, J Clin Pathol, 65, 823, 10.1136/jclinpath-2012-200881 · DOI
- Kumar, 2010, Immunophenotyping in multiple myeloma and related plasma cell disorders, Best Pract Res Clin Haematol, 23, 433, 10.1016/j.beha.2010.09.002 · DOI
- Paiva, 2010, Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders, Cytometry B Clin Cytom, 78, 239, 10.1002/cyto.b.20512 · DOI · Paper page
- Ocqueteau, 1996, Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells, Br J Haematol, 95, 489, 10.1111/j.1365-2141.1996.tb08993.x · DOI
- Montero, 2008, Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity, Haematologica, 93, 851, 10.3324/haematol.12171 · DOI
- Schmidt-Hieber, 2011, CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features, Haematologica, 96, 328, 10.3324/haematol.2010.031872 · doi:10.3324/haematol.2010.031872
- Mateo, 2008, Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy, J Clin Oncol, 26, 2737, 10.1200/JCO.2007.15.4120 · DOI · Paper page
- Cannizzo, 2012, The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model, Am J Clin Pathol, 137, 377, 10.1309/AJCP63TOCFNAMDMS · DOI
- Bataille, 2008, CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis, Leuk Res, 32, 379, 10.1016/j.leukres.2007.07.016 · DOI
- Grigoriadis, 2012, Is CD20 positive plasma cell myeloma a unique clinicopathological entity? A study of 40 cases and review of the literature, Pathology, 44, 552, 10.1097/PAT.0b013e3283583f5d · DOI
- Moreau, 2007, Rituximab in CD20 positive multiple myeloma, Leukemia, 21, 835, 10.1038/sj.leu.2404558 · DOI
- Robillard, 2005, CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target, Leukemia, 19, 2021, 10.1038/sj.leu.2403948 · DOI
Cited by
Flores‐Montero, J., de Tute, R., Paiva, B., Perez, J. J., Böttcher, S., Wind, H., Sanoja, L., Puig, N., Lecrevisse, Q., Vidriales, M. B., et al. (2016) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21265 · Cited by 261
The maintenance of memory plasma cells
Khodadadi, L., Cheng, Q., Radbruch, A., & Hiepe, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00721 · Cited by 232
“However, there is a diverse range of phenotypic markers of plasma cells (65).”
BackgroundAkidil, E., Albanese, M., Buschle, A., Ruhle, A., Pich, D., Keppler, O. T., & Hammerschmidt, W. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009117 · Cited by 31
Metadata
- Authors
- Robillard, N., Wuillème, S., Moreau, P., & Béné, M. C.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2014-03-31
- Volume
- 5
- ISSN
- 1664-3224
- Cited by
- 82
- References
- 0
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets. https://app.cochat.ai/papers/10.3389/fimmu.2014.00137
- The paper
- Robillard, N., Wuillème, S., Moreau, P., & Béné, M. C. (2014). Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2014.00137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.